Catálogo de publicaciones - libros

Palabras clave – provistas por la editorial

multiple myeloma; STAT3; S3I-1757; nanoparticle; CD38; siRNA/RNAi; polyethylenimine; PEI; lipopolyplex; siRNA delivery; glioma; glioblastoma; STAT5; AKT; ERK1/2; prolactin; androgens; prostate cancer; knockout; escape mechanisms; stem/progenitor cells; cell hierarchy; cancer; CD4+ T cells; CD8+ T cells; myeloid cells; immune check point; hepatitis C virus (HCV); cirrhosis; hepatocellular carcinoma (HCC); endoplasmic reticulum (ER) stress; oxidative stress (OS); unfolded protein response (UPR); microRNA-122 (miR-122); nuclear factor erythroid 2-related factor 2 (NRF2); signal transducer and activator of transcription 3 (STAT3); hepatocyte nuclear factor 4 alpha (HNF4A); solid cancers; cell cycle; apoptosis; inflammation; mitochondria; stemness; tumor suppression; melanoma; autoimmune disease; immunotherapy; tumor–immune cell interactions; breast cancer; PD-L1; M2 macrophages; NK cells; STAT3 inhibitor XIII; hedging; transaction costs; dynamic programming; risk management; post-decision state variable; cancer progression; cancer-stem cell; cytokine; therapy resistance; metastasis; immunosuppression; tumor microenvironment; proliferation; tyrosine kinase 2; JAK family of protein tyrosine kinases; signal transducer and activator of transcription; cytokine receptor signaling; gain-of-function mutation; tumorigenesis; ADAM17; interleukin-6; trans-signaling; epidermal growth factor receptor (EGF-R); shedding; metalloprotease; tumor necrosis factor alpha (TNFα); inflammation associated cancer; colon cancer; lung cancer; SH2 domain; mutations; autosomal-dominant hyper IgE syndrome; inflammatory hepatocellular adenomas; T-cell large granular lymphocytic leukemia; T-cell prolymphocytic leukemia; growth hormone insensitivity syndrome; nuclear pore complex; nuclear transport receptors; nucleocytoplasmic shuttling; targeting; tumor-associated macrophages; adoptive T cell therapy; immune suppression; STAT transcription factors; JAK; STAT; T-PLL; T-cell leukemia; meta-analysis; STAT5B signaling; small-molecule inhibitors; cancer models; companion animals; comparative oncology; pharmacological inhibitor; STAT5 signaling; chemotherapy resistance; myeloid leukemia; heat shock proteins; chaperones; stabilization; targeted therapy; ovarian cancer; hematopoietic cancers; therapeutic targeting; pharmacological inhibitors; mTOR; Bone Marrow Failure Syndromes; lymphocytes; lymphoma; T-cells; RHOA; NGS; MPN; JAK2 V617F; neoplastic stem cells; n/a